← All trials
NCT05477446
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2022
- Primary completion
- Jun 1, 2025
- Completion date
- Aug 1, 2025
- First posted
- Jul 28, 2022
- Last posted
- Jul 28, 2022
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Capital Medical UniversityOverall official - principal investigator
- Capital Medical UniversityReponsible party - principal investigator
- Beijing Boren HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.